Skip to main content
Clinical Trials/CTRI/2025/11/098172
CTRI/2025/11/098172RecruitingPhase 2

Randomized Controlled Trial evaluating Ayurvedic therapies- Siro pichu and Padabhyanga with Ksirabala Taila as an Add on to Cognitive Behavioural Therapy-Insomnia (CBT-I) for the management of Insomnia in Perimenopausal Women

Amrita School of Ayurveda1 site in 1 country62 target enrollmentStarted: December 9, 2025Last updated:

Trial Snapshot

Phase
Phase 2
Status
Recruiting
Sponsor
Enrollment
62
Locations
1
Primary Endpoint
Change in Insomnia Severity Index total score and Pittsburgh Sleep Quality Index score from baseline to end of intervention

Study Overview

Brief Summary

The single centre parallel group randomized controlled trial is designed to evaluate the efficacy of Ayurvedic therapies Siro pichu and Padabhyanga with Ksirabala Taila as adjuncts to Cognitive Behavioural Therapy for Insomnia in the management of chronic insomnia among perimenopausal women aged 45 to 55 years. Insomnia affects nearly half of women during the menopausal transition and while CBT I is the recommended first line non pharmacological treatment it often requires 4 to 6 weeks for noticeable improvement leading to early discontinuation in up to 30 to 40 percent of patients. Ayurvedic therapies targeting Vata imbalance such as Siro pichu and Padabhyanga are traditionally used to induce relaxation and sleep with preclinical evidence suggesting effects on GABAergic modulation and parasympathetic activation. The trial will enroll eligible women with subthreshold to moderate insomnia after screening and informed consent. Participants will be randomized into two groups: the intervention group will receive CBT I along with Siro pichu for 30 minutes nightly for 7 days and Padabhyanga for twice daily for 14 days while the control group will receive CBT I alone. CBT I will be delivered to both groups through eight standardized sessions over four weeks, supplemented by sleep hygiene counselling. The primary outcomes are mean reduction in the Insomnia Severity Index and Pittsburgh Sleep Quality Index scores after four weeks. Secondary outcomes include early improvement in ISI scores at two weeks, sustained changes in ISI and PSQI during a three month follow up occurrence of adverse events and dependency risk assessed using the Severity of Dependency Scale, and adherence assessed by daily diaries. All Ayurvedic medicines will be sourced from a GMP certified manufacturer and administered under standard operating procedures. Safety will be closely monitored and rescue measures will be available if required. This academic trial, conducted at the Department of Prasuti Tantra and Stri Roga Amrita Ayurveda Hospital aims to generate evidence on whether integrating Ayurvedic therapies with CBT I can provide faster symptomatic relief enhance adherence and sustain sleep benefits without pharmacological risks in perimenopausal women with insomnia.

Study Design

Study Type
Interventional
Allocation
Randomized
Masking
None

Eligibility Criteria

Ages
45.00 Year(s) to 55.00 Year(s) (—)
Sex
Female

Inclusion Criteria

  • Women aged 45 to 55 years Insomnia Severity Index(ISI ) score in between 8-21; identified by symptoms of difficulty initiating or maintaining sleep, or early morning awakening, occurring at least three nights per week, persisting for a minimum duration of three months, and associated with clinically significant distress or impairment in daytime functioning.
  • Able to understand and comply with CBT instructions.
  • Able to provide written informed consent.

Exclusion Criteria

  • Known cases of Hypertension, Thyroid disorders, and Diabetes Mellitus.
  • Those who require HRT during their menopausal period.
  • PHQ-9 Depression scale Score greater than
  • Under medication for any psychological or psychiatric disorders & substance use in the past 30 days.
  • Any active medical or neurological conditions causing sleep disruption.
  • No access to mobile phones and internet.
  • Use of sleep inducing medications, anti depressants, anti psychotics or sedatives in the past 30 days BMI greater than 35.

Outcomes

Primary Outcomes

Change in Insomnia Severity Index total score and Pittsburgh Sleep Quality Index score from baseline to end of intervention

Time Frame: Primary Outcome will be assessed at baseline and at four weeks of intervention

Secondary Outcomes

  • Early therapeutic response assessed using Insomnia Severity Index total score at Week 2; longitudinal change in Insomnia Severity Index total score during follow up at Weeks 6 8 10 and 12; change in Pittsburgh Sleep Quality Index score during follow up at Weeks 4 8 and 12; occurrence and characterization of clinically relevant events using validated adverse event and adverse drug reaction monitoring checklist; behavioural dependency risk assessed using Severity of Dependency Scale total score; treatment adherence and fidelity assessed using Daily Sleep and Treatment Engagement Diary(Week 2 Weeks 4 6 8 10 and 12 Baseline to Week 12 and daily during intervention)

Investigators

Sponsor
Amrita School of Ayurveda
Sponsor Class
Other [Academic Institution]
Responsible Party
Principal Investigator
Principal Investigator

Parvathy Unnikrishnan

Amrita School of Ayurveda

Study Sites (1)

Loading locations...

Similar Trials